ProLindac Demonstrates Sustained and Significant Reductions in Cancer
DALLAS, May 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that the company gave an invited oral presentation on its lead anticancer compound, ProLindac(TM) at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice, taking place from May 26-28 in Valencia, Spain. The presentation was entitled "Promising Safety and Efficacy Results from an Ongoing Clinical Study of ProLindac in Recurrent Ovarian Cancer." ProLindac is Access' novel DACH platinum-polymer prodrug, which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials.
The invited presentation was given by Professor Esteban Cvitkovic, M.D., Access Pharmaceuticals' Senior Director, Clinical Oncology R&D. Professor Cvitkovic presented data from the ongoing Phase 2 monotherapy clinical study of ProLindac in patients with recurrent ovarian cancer. In two dosing regimens, ProLindac was given once every two weeks and once every three weeks. During the last and highest dose levels explored, sustained and significant reductions in the specific serum market Ca-125 were seen over multiple dosings in several patients. ProLindac was well-tolerated with minimal side-effects.
"We continue to be impressed by clinical results that indicate a significant DACH platinum drug effect with a very benign side effect profile," stated Jeffrey B. Davis, Access' President & CEO. "The sustained efficacy and minimal toxicity seen over multiple dosings provides further evidence that ProLindac has the potential to become a very important anticancer agent in the future. We are finalizing our plans for Phase 2 combination trials where we intend to look at multiple solid tumor types with ProLindac in combination with other cancer agents, like taxol and gemcitabine."
ProLindac is currently in a Phase 2 dose-escalating monotherapy trial in recurrent ovarian cancer. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin(TM) or oxaliplatin.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; and Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Report on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved